Celator's blood cancer drug enters clinical trial

09/22/2013 | Pharmaceutical Business Review Online

Celator Pharmaceuticals said it has signed up the first patient for a clinical trial of its experimental drug CPX-351 Liposome Injection. The two-phase trial will evaluate the efficacy, tolerability and pharmacokinetics of the drug, which contains cytarabine and daunorubicin, in children and young adults with aggressive lymphoma, acute myeloid leukemia and acute lymphoblastic leukemia.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY